Vifor Pharma announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical study aims to better understand renin-angiotensin-aldosterone system inhibitors (RAASi) treatment decisions in clinical practice, potential barriers to achieving optimal guideline-directed care in HF patients with or at high risk for HK, and to assess how Veltassa® may be used in the management of this patient population.

Dr. Mikhail Kosiborod, cardiologist and Vice President of Research at Saint Luke's Health System, explains how the registry is the first of its kind and how it will help optimize the quality of patient care.

Read the full Business Wire article: First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment